Imbalance Associated With Cisplatin Chemotherapy in Adult Cancer Survivors: A Clinical Study
- PMID: 33606465
- DOI: 10.1097/MAO.0000000000003079
Imbalance Associated With Cisplatin Chemotherapy in Adult Cancer Survivors: A Clinical Study
Abstract
Objective: This study investigated balance problems and vestibular function in adult cancer survivors who had completed cisplatin chemotherapy treatment.
Study design: Observational cross-sectional study.
Setting: Tertiary care center.
Patients: Adult survivors of cancer who had completed cisplatin treatment.
Main outcome measures: Patient-reported balance symptoms were evaluated by a semistructured clinical interview. Patients underwent bedside clinical tests including Dynamic Visual Acuity test, Modified Clinical Testing of Sensory Interaction and Balance (CTSIB-m), and vibration sense testing to detect peripheral neuropathy. The video Head Impulse Test (vHIT) of all semicircular canals was performed.
Results: Eleven of 65 patients (17%) reported some balance symptoms after cisplatin therapy, including vertigo, dizziness, unsteadiness, and falls. Vertigo was the most common balance symptom, reported by six patients (9.2%), and the clinical histories of these patients were consistent with benign paroxysmal positional vertigo. Three patients (5%) had abnormal results of the CTSIB-m test, and they were the same patients who reported falls. There was a significant association of peripheral neuropathy detected by vibration test and balance symptoms. All patients had normal vHIT results in all semicircular canals.
Conclusions: Balance symptoms after cisplatin treatment occurred in 17% of adult cancer survivors. Patients with peripheral neuropathy were more likely to have balance symptoms. The CTSIB-m test is a useful bedside physical examination to identify patients with a high risk of fall. Though there was no vestibular dysfunction detected by the vHIT in cancer survivors after cisplatin therapy, benign paroxysmal positional vertigo was relatively prevalent in this group of patients.
Copyright © 2020, Otology & Neurotology, Inc.
Conflict of interest statement
The authors disclose no conflicts of interest.
References
-
- Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740:364–378.
-
- Bronstein AM. Multisensory integration in balance control. Handb Clin Neurol 2016; 137:57–66.
-
- Myers SF, Blakley BW, Schwan S. Is cis-platinum vestibulotoxic? Otolaryngol Head Neck Surg 1993; 108:322–328.
-
- Waissbluth S, Chuang A, Del Valle A, Cordova M. Long term platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol 2018; 107:75–79.
-
- Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 2016; 34:2712–2720.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
